Transforming Arrhythmia Therapy
About UsLuxMed has developed the first and only image-guided therapeutic ablation catheter with optical tissue interrogation providing real-time lesion and gap detection. Its therapeutic ablation catheters are designed to optically identify all tissue needing to be ablated fueling improved clinical outcomes, faster procedure times and reduced costly repeat ablations.
|
|
Technology
LuxMed has integrated proprietary optics
into therapeutic ablation catheters enabling
electrophysiologists to optically assess
heart tissue’s composition and
metabolic activity for the first time during
the ablation procedure.
Real-time heart tissue optical signatures
demonstrate tissue contact, tissue viability,
lesion formation and lesion progression
in response to cardiac ablation during the
procedure. LuxMed is commercializing
optically enabled radiofrequency ablation
catheters first followed by pulsed field
ablation catheters (PFA or electroporation).
into therapeutic ablation catheters enabling
electrophysiologists to optically assess
heart tissue’s composition and
metabolic activity for the first time during
the ablation procedure.
Real-time heart tissue optical signatures
demonstrate tissue contact, tissue viability,
lesion formation and lesion progression
in response to cardiac ablation during the
procedure. LuxMed is commercializing
optically enabled radiofrequency ablation
catheters first followed by pulsed field
ablation catheters (PFA or electroporation).
Core Capabilities
Lesion & Gap Detection
Contact Stability
|
Lesion Progression
Catheter Movement
|
Catheter Contact
Tissue Composition
|
Progress
Clinically Validated
Tested in patients with cardiac arrhythmias including A-Fib |
Extensive Preclinical Data
Core capabilities demonstrated in several animal model studies |
Robust IP Portfolio
34 issued patents 30+ pending |
Posters
HRS 2019
HRS 2016
|
HRS 2019
Supported by Leading World Renowned Electrophysiologists |
HRS 2016
HRS 2015
|
Founders & Management Team
|
Omar Amirana, MD, Co-Founder, President, Chief Executive Officer, and Board Director
Omar Amirana, M.D. is Co-Founder, President & Chief Executive Officer, and member of the Board of Directors of LuxMed Systems, Inc. Dr. Amirana has over 25 years of experience in electrophysiology. He co-founded Cardima, Inc., a Silicon Valley EP company where he served for seven years as Vice President of Sales and Marketing, Business Development and Chief Technical Officer. He launched Cardima products worldwide and went on their IPO roadshow. He also previously worked at EP Technologies, the first company to develop a radiofrequency cardiac ablation catheter which was acquired by Boston Scientific after going public. He currently serves on the Board of Directors for Cardiofocus Inc. and CathRx Ltd, both revenue stage EP companies. Prior to founding LuxMed Systems, Dr. Amirana served as Senior Vice President of Allied Minds, an IP commercialization firm investing in the life sciences and technology sectors, which went public on the London Stock Exchange. There he founded, funded and managed various startups and the life sciences portfolio. He served as a Partner at Oxford Bioscience Partners, a Boston-based traditional life sciences venture capital firm, focusing on medical device investing. He was also Vice President of Business Development for the Daig (EP) Division at St. Jude Medical prior to its acquisition by Abbott. Dr. Amirana has an M.D. from Eastern Virginia Medical School and a B.S. in Mechanical Engineering from Tufts University. |
|
Terry Ransbury, Co-Founder, Chief Technology Officer, and Board Director
Terry Ransbury is a Co-Founder, Chief Technology Officer and member of the Board of Directors of LuxMed Systems, Inc. Mr. Ransbury is a serial entrepreneur and brings over 35 years of experience in electrophysiology and cardiac rhythm management. He has extensive experience developing Class II and III medical devices and has filed over 40 patents. Mr. Ransbury is also EP-lab certified and has participated in over 600 human cardiac ablation procedures around the world. Prior to co-founding LuxMed Systems, Mr. Ransbury founded and led Nocturnal Product Development, a medical device product development firm. He was also the first employee at InnerPulse, an intravascular defibrillator company, where he served as Vice President of Research & Development for over eight years. Before InnerPulse, Mr. Ransbury was employee number 14 at Ventritex, a medical device company engaged in the development of an implantable heart defibrillator, where he served as an Engineering Manager for ten years before the company was acquired by St. Jude Medical (now Abbott) in 1996. Prior to Ventritex, Mr. Ransbury served as a Regional Clinical Manager at Biosense Webster. Mr. Ransbury holds a B.S. degree in Biomedical and Electrical Engineering from Duke University. |
|
John A. McCarthy, Jr., Co-Founder, Chief Business Officer, and Board Director
John McCarthy is a Co-Founder and serves as Chief Business Officer and member of the Board of Directors at LuxMed Systems, Inc. Mr. McCarthy has over 30 years leading the transformational growth of numerous science and technology-focused companies from early-stage organizations into successful commercial entities, both in the private and public capital markets (including 3 IPOs). His track record includes successfully raising more than $1 billion across the broad capital markets, as well as developing, executing and managing numerous precedent-setting strategic corporate partnerships. Mr. McCarthy has served as the CEO of a number of life sciences companies, and has held various executive positions at leading companies, including: Verenium Corporation, Exact Sciences Corporation, and Concentra Managed Care, Inc. Prior to his operating experience, Mr. McCarthy worked in the Investment Banking Group of Morgan Stanley. Mr. McCarthy previously served as a Board member of publicly-traded InVivo Therapeutics (having served as Board Chairman and Audit Committee Chairman), InfoMedtrics, Signet Laboratories, and the Harvard Business School Alumni Association. Mr. McCarthy holds an M.B.A from Harvard University and a B.S. from Lehigh University. |
|
Arun Jaganathan, Co-Founder, Vice President of Strategy & Marketing, and Board Observer
Arun Jaganathan is a Co-Founder, Vice President, Strategy and Marketing, and Board Observer of LuxMed Systems, Inc. Mr. Jaganathan has 15 years of experience in the life sciences industry across a variety of roles including venture investing, corporate strategy, business development and startup operations and management. Most recently, Mr. Jaganathan served as a Director of Allied Minds, an IP commercialization firm based in Boston, where he sourced and evaluated new life sciences investment opportunities, focusing on medical devices and digital health technologies. He also served as the General Manager for several medical device companies, including Signature Medical, Inc., a heart failure wearable device company. Mr. Jaganathan also served as a member of the corporate strategy and business development team at Boston Scientific. Before Boston Scientific, Mr. Jaganathan was a strategy consultant at Fletcher Spaght, Inc., a boutique healthcare consulting firm in Boston. Mr. Jaganathan holds a Master’s in biotechnology from Columbia University and a Bachelor’s degree in Microbiology & Immunology from McGill University in Montreal, QC. |
Independent Directors & Advisors
|
R. John Fletcher, Independent Board Director
John Fletcher is an Independent Director of LuxMed Systems, Inc. Mr. Fletcher brings over 35 years of healthcare and medical device experience and currently serves as Chief Exeuctive Officer and Managing Director of Fletcher Spaght Inc., a strategy consulting and venture capital firm which he founded in 1983. Prior to founding Fletcher Spaght, he was Senior Manager at The Boston Consulting Group, advising a broad range of companies in healthcare and high technology industries. In 2002, Mr. Fletcher joined the Board of Directors of publicly-traded medical device company Spectranetics Corporation and served as Chairman of the Board from 2010-2017. During his 15-year tenure as a member of the board, Spectranetics expanded its therapeutic platforms and generated significant commercial growth. In August 2017 Spectranetics was acquired by Royal Philips in a transaction valued at $2.2 billion. Mr. Fletcher was named 2018 Director of the Year by The National Association of Corporate Directors (NACD) for his work at Spectranetics. Mr. Fletcher currently serves on the Board of Directors of Axcelis Corporation, MRI Interventions and is Chairman of Metabolon. He is also Chairman Emeritus of the Corporate Collaboration Council at the Thayer School of Engineering/Tuck School of Business at Dartmouth College and serves on the Board of Advisors of Beth Israel Deaconess Medical Center and the Whitehead Institute at MIT. Mr. Fletcher received his MBA from Southern Illinois University and a BBA in Marketing from George Washington University. He was an Instructor for courses in international business and a Ph.D. Candidate at the Wharton School of the University of Pennsylvania. Mr. Fletcher served as a Captain and jet pilot in the United States Air Force. |
|
Rick Randall, Independent Board Director
Rick Randall is an Independent Director of LuxMed Systems, Inc. Mr. Randall has over 40 years of experience in the medical device industry, primarily focused on introducing novel, minimally invasive therapeutic products to global markets. Most recently, Mr. Randall served as Chief Executive Officer of OMNIlife Science, Inc., the first company to commercialize Robotic Assisted Total Knee Replacement in the United States. Before OMNI, he served as Chief Executive Officer of Innovasive Devices, Inc. (acquired by Johnson & Johnson in 2000), and Target Therapeutics, Inc. (acquired by Boston Scientific in 1997.) He also served as the Chief Executive Officer of Avantis Medical Systems, Medical Compression Systems and TranS1. In addition, Mr. Randall currently serves as a Director at Scientia Vascular and Fortus Medical, Inc and is an Advisor at 206 Ortho, Inc. He was previously an Advisor to the Board at RadiaDyne, LLC, acquired by AngioDynamics. Mr. Randall has previously served on the boards of TranS1, Endocardial Solutions, Inc. and Conceptus, Inc. Mr. Randall has a Bachelor’s of Science from SUNY Buffalo. |
|
Daniel Levangie, Advisor
Daniel Levangie is an experienced executive and corporate director with senior operating experience in the field of medical devices and in vitro diagnostics. He is currently cofounder and Managing Partner of ATON Partners, a private investment firm and Chairman, President & CEO of CereVasc, LLC, an early stage medical device company. Until January 2017 Mr. Levangie was President of Insulet Drug Delivery Systems following his tenure as Lead Independent Director of Insulet Corporation. From 2011 through 2013 Mr. Levangie served as Chief Executive Officer of Dune Medical Devices while remaining as co-founder and Managing Partner of Constitution Medical Investors, Inc. (CMI) a Boston-based private investment and product development firm acquired by Roche Diagnostics Corporation in July 2013. Prior to the above, Mr. Levangie held a variety of executive management positions with Cytyc Corporation until the acquisition of Cytyc Corporation by Hologic, Inc. in October of 2007. Those positions included Executive Vice President and Chief Operating Officer, Chief Executive Officer and President of Cytyc Health Corporation, Executive Vice President and Chief Commercial Officer and President, Cytyc Surgical Products Division. Prior to joining Cytyc Corporation in 1992, Mr. Levangie held a number of sales, marketing and management positions with Abbott Laboratories, North Chicago, IL. Mr. Levangie resides in Boston, MA with his wife Joan, and is a member of the Board of Directors of Exact Sciences, Inc., (EXAS: NASDAQ) Dune Medical Devices, Renovia, Inc. and CereVasc, LLC. Mr. Levangie, a graduate of the College of Pharmacy of Northeastern University in Boston, is a member of the Advisory Board of the Barnett Institute of Northeastern University and is a trustee of Excel Charter School, East Boston. |
|
Narine Sarvazyan PhD, Advisor
Dr. Sarvazyan is an accomplished professor, academic researcher and inventor in the field of cardiac physiology. She serves as Professor of Pharmacology and Physiology at the George Washington University in Washington, D.C. Sarvazyan brings over 30 years of highly specialized knowledge in cardiac cell physiology, mechanisms of arrhythmias, live visualization of ablation lesions, tissue engineering, stem cell based cardiovascular repair. Dr. Sarvazyan has been published extensively across various renowned peer-reviewed journals and holds several patents in her name. She served as a PI on multiple NIH and NSF grants, and is a recipient of the prestigious Established Investigator Award from the American Heart Association and the Fulbright Scholar Award from the US State Department. |
Scientific Advisory Board
|
Jeremy Ruskin, MD
Dr. Jeremy Ruskin is the Founder and Director Emeritus of Cardiac Arrhythmia Service at the Massachusetts General Hospital (MGH) and Professor of Medicine at Harvard Medical School. In this role, Dr. Ruskin has been responsible for the training of more than 120 fellows in cardiac electrophysiology, many of whom are leaders in the field. His research focuses on new technologies for catheter ablation of atrial fibrillation, mechanisms and prevention of ventricular arrhythmias and sudden cardiac death, risk stratification for sudden death, and cardiac safety issues in new drug and device development. He is an author of more than 450 scientific publications and has been the recipient of multiple awards including the 1997 Michel Mirowski Award for Excellence in Clinical Cardiology and Electrophysiology and the 2002 Heart Rhythm Society Pioneer in Pacing and Electrophysiology Award. Most recently, Dr. Ruskin received the William Silen Lifetime Achievement in Mentoring Award at Harvard Medical School. Dr. Ruskin received his undergraduate degree from Tufts University and his medical degree from Harvard Medical School. He completed his residency in Internal Medicine at Beth Israel Hospital Boston and his fellowship in Cardiovascular Disease at the MGH. He received his training in clinical cardiac electrophysiology at the USPHS Hospital in Staten Island, New York under the mentorship of Dr. Anthony Damato. |
|
Vivek Y. Reddy, MD
Dr. Vivek Reddy is the Director of Cardiac Arrhythmia Services for The Mount Sinai Hospital and the Mount Sinai Health System, and The Leona M. and Harry B. Helmsley Charitable Trust Professor of Medicine in Cardiac Electrophysiology at Icahn School of Medicine at Mount Sinai. Dr. Reddy is one of the nation’s premier cardiac electrophysiologists, leading a team of physician-scientists who are developing and testing advanced therapies for cardiac arrhythmias – including atrial fibrillation and ventricular tachycardias, the most common cause of sudden cardiac death. Dr. Reddy’s pioneering clinical research is changing the way cardiac patients are treated and cured. Under his leadership, Mount Sinai is the lead investigator on several multinational clinical trials exploring new arrhythmia procedures and technologies. Dr. Reddy received his medical degree from the University of Michigan Medical School. |
|
David E. Haines, MD
Dr. David Haines is Director of the Heart Rhythm Center and Professor of Cardiovascular Medicine at Beaumont Health System and Oakland University William Beaumont School of Medicine. He has served on several Heart Rhythm Society committees, and has been the HRS liaison for other organizations including the Intersocietal Accreditation Commission and the Multispecialty Occupational Health Group. During his time at UVA, Dr. Haines held positions of Director, Cardiovascular Fellowship Training Program; Director, Clinical Cardiovascular Electrophysiology Fellowship Training Program and Co-Director, Cardiac Electrophysiology Laboratory. In 2003, Dr. Haines accepted the position of Director of the Heart Rhythm Center at William Beaumont Hospital, Royal Oak, Michigan. Dr. Haines also served as Interim Chair of Cardiovascular Medicine at Beaumont from 2006 through 2010. Dr. Haines received his medical degree from the University of Rochester School of Medicine and Dentistry. |
|
Andrea Natale, MD
Dr. Andrea Natale is a world recognized leader in the field of electrophysiology who specializes in the use of percutaneous catheter ablation to treat complex atrial fibrillation. He currently serves as Executive Medical Director, Texas Cardiac Arrhythmia Institute at St. David’s Medical Center. Dr. Natale pioneered a circumferential ultrasound vein-ablation system used to correct atrial fibrillation, performing the world’s first five procedures. He was the nation’s first electrophysiologist to perform percutaneous epicardial radiofrequency ablation, a treatment for patients who fail conventional ablation. Prior to the establishment of Texas Cardiac Arrhythmia Institute at St. David’s Medical Center, Dr. Natale was a member of the Cardiovascular Medicine Department at the Cleveland Clinic from 1999 to 2007, serving most recently as Section Head for the Department of Cardiac Pacing and Electrophysiology and as Medical Director for the Cleveland Clinic’s Center for Atrial Fibrillation. In 2006, Dr. Natale was named to the Food and Drug Administration’s Task Force on Atrial Fibrillation. In addition, Dr. Natale was previously the head of cardiovascular physiopathology at the Italian Air Force’s Aerospace Research Centre and served as director of the electrophysiology laboratory at Duke University and director of the electrophysiology program at the University of Kentucky, Lexington. Dr. Natale received his medical degree from Universita’ degli Studi di Firenze, School of Medicine and Surgery, in Florence, Italy. |